Abstract
Mumps and rubella are vaccine-preventable viral diseases through the measles-mumps-rubella-varicella (MMRV) vaccine, administered at 12 months and again at 6 years. We assessed the sero-prevalence of mumps and rubella, identified factors associated with sero-negativity, and eval-uated concordance between mumps and rubella sero-positivity. A national cross-sectional sero-sur-vey was conducted on samples collected in 2015 by the Israel National Sera Bank. Samples were tested for mumps and rubella IgG antibodies using an enzyme-linked immunosorbent assay. Of 3131 samples tested for mumps IgG, 84.8% (95%CI: 83.5–86.0%) were sero-positive. Sero-negativity for mumps was significantly associated with age (high odds ratios observed in infants younger than 4 years and 20–29 years old subjects). Of 3169 samples tested for rubella IgG antibodies, 95.2% (95%CI: 94.4–95.9%) were sero-positive. Rubella sero-negativity was significantly associated with age (high odds ratios observed in children younger than 4 years old and adults older than 30 years), males, Jews, and others. Concordant sero-positivity for both mumps and rubella viruses was observed in 83.9% of the tested samples. The Israeli population was sufficiently protected against rubella but not against mumps. Since both components are administered in the MMRV vaccine sim-ultaneously, the mumps component has a lower uptake than rubella and quicker waning.
Original language | English |
---|---|
Article number | 996 |
Journal | Vaccines |
Volume | 10 |
Issue number | 7 |
DOIs | |
State | Published - 1 Jul 2022 |
Keywords
- mumps
- rubella
- sero-prevalence
- vaccine
- virus
All Science Journal Classification (ASJC) codes
- Drug Discovery
- Infectious Diseases
- Pharmacology (medical)
- Pharmacology
- Immunology